February 2019

Targeting TP53 Mutations in Myelodysplastic Syndromes

David Sallman, MD
Assistant Member, Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Read Here

January 2019

Mutation Clearance after Transplantation for Myelodysplastic Syndrome

Minimal residual disease monitoring in haematological malignancies is seen as standard of care in the evaluation of response to treatment and the prediction of relapse risk. This article considers the potential benefit of molecular monitoring after transplantation for myelodysplastic syndrome.

Read Here

Paper of the Month

Targeting TP53 Mutations in Myelodysplastic Syndromes

David Sallman, MD
Assistant Member, Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Read Here

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

calculator

Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

calculator

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BCSH Guideline

This is an external  link to the home of the British Society for Haematology (BSH). 

bsh logo

Click here